Join Quotient Sciences' Executive Director of Drug Development Solutions, Kieran Crowley, on Monday, March 16th for a lunch seminar entitled: Analysis from the Tufts Center for the Study of Drug Development (CSDD) on the financial benefits of Translational Pharmaceutics: an integrated approach for accelerating drug development
Date: Monday, March 16th
Where: BIOCOM- 10996 Torreyana Rd #200, San Diego, CA 92121
11:00am to 11:30am - Registration & Lunch
11:30am to 12:30pm - Seminar
12:30pm to 1:00pm - Q&A
Presentation Summary: The drug development process has been demonstrated to be costly and lengthy, with significant rates of molecule attrition and development risk. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier. To inform drug developers of the time savings and potential financial impacts of alternative drug development processes and outsourcing models, the Tufts CSDD conducted a study comparing the traditional drug development paradigm with Quotient Sciences’ signature drug development platform, referred to as Translational Pharmaceutics®. Translational Pharmaceutics is widely used by pharmaceutical and biotech companies to accelerate product development. Key applications of Translational Pharmaceutics include the transition of molecules from First in Human (FIH) to Proof of Concept (POC), and in the development and optimization of clinical formulations. This presentation will summarize the key findings of the Tufts CSDD research, which reported a mean reduction in development cycle times of over 12 months and overall financial gains of at least $100m per approved drug.